Generic Name: Palbociclib

Mechanism of Action:
Palbocap is a selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. Cyclin D1 and CDK4/6 are downstream of signaling pathways, which lead to cellular proliferation.
Palbocap reduces proliferation of breast cancer cells by preventing G1 to S phase cell cycle progression.

Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• An aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men
• Fulvestrant in patients with disease progression following endocrine therapy.
Dosage Form and Strengths:
Capsules: 125 mg, 100 mg, 75 mg
Supplied in HDPE bottles containing 21 capsules.
A capsule should be taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbocap should be taken with food.